Combines Illumina’s decentralized installed base with Roche’s assay development to provide broad access to clinical oncology next-generation sequencing.
Firms to address combo drug or device with digital health, digital therapeutics, blockchain, and software as a medical device platform in clinical development.
Addition of the cobas TV/MG test to the testing menu provides the flexibility to process up to four sexually transmitted infections from one patient sample.